Sobi’s Gamifant (emapalumab) Received Recommendation for Approval in China from CDE to Treat Adult and Paediatric Patients with Primary Haemophagocytic Lymphohistiocytosis
Shots:
- CDE has recommended to NMPA for the approval of Gamifant in China to treat adult and paediatric patients with primary HLH with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy
- Gamifant is a monoclonal antibody that binds and neutralises the IFNy. It is the first approved treatment in the US and UAE for primary HLH
- In Sep 2020, emapalumab received ODD by the FDA for prevention of graft failure following hematopoietic stem cell transplantation
Ref: PR Newswire | Image: Sobi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
